Hawkeye is focused on the early detection of cancer, neurodegenerative disease and inflammatory conditions. The company’s lead program is in Lung Cancer (ProLung).

Today 70-80% of lung cancer cases are detected at Stage III/IV, when curative treatment is challenging if not impossible. The ProLung blood test stage-shifts lung cancer detection to Stage I/II when treatment can be more successful.

ProLung performs with 95% sensitivity at Stage I, 99.8% negative predictive value and is 100% patient safe.

Lung cancer is a growing problem among non-smokers and younger individuals who are excluded from national lung cancer screening guidelines that are based on age and smoking history. We hope that in the not-too-distant future ProLung will help identify all at-risk individuals earlier so they can seek medical care.

The Hawkeye team includes medical professionals with three-decades of success in oncology, medical practice and liquid biopsy clinical development.

Founded in 2019 and privately held, Hawkeye is based in Los Angeles and Ireland.